Supplier issues massive recall of frozen hash browns sold nationwide after dangerous contaminant found: 'Should be discarded or returned'
As Food Safety News detailed in early May, Lamb Weston Inc. recalled a whopping 34,801 cases of its frozen Lamb Weston Hashbrown Patties due to "the presence of foreign material, specifically plastic pieces ranging from 1 millimeter to 8 millimeters in size."
The recall was initiated on April 19 and remains ongoing, the U.S. Food and Drug Administration told Food Safety News.
The Class II recall indicates "a low risk" of serious health consequences, though temporary or reversible effects remain a possibility. The products included in the recall were distributed to Arizona and Hawai'i, as well as internationally to Japan, Kuwait, Taiwan, and the United Arab Emirates.
"Consumers who have purchased the recalled Lamb Weston Hashbrown Patties are urged not to consume them," Food Safety News stated. "The products should be discarded or returned to the place of purchase."
While no adverse reactions were reported at the time of the recall, this issue highlights the dangers of plastic pollution.
As Food Safety News noted, "the presence of plastic pieces in food products poses risks such as choking, oral injury, or gastrointestinal damage if ingested."
Unfortunately, this issue is becoming far too common. Even a major company like Kraft Heinz had to recall thousands of cases of its Singles American cheese due to a machine error that left plastic in the slices.
The recall was triggered after customers had reported choking or gagging incidents, and Kraft advised returning affected products to the store for a full refund.
These instances also raise concerns for microplastic consumption, as these tiny particles are already incredibly invasive, accumulating in the environment and even inside our bodies.
Do you think we use too much plastic in America?
Definitely
Only some people
Not really
I'm not sure
Click your choice to see results and speak your mind.
The health effects are still being determined, but microplastics have already been linked to cancer and neurodegenerative diseases such as Parkinson's and ALS.
Microplastics can be found everywhere, from the air we breathe to the food we eat, so ingesting food contaminated with plastic creates even more risks to our health.
Any consumers experiencing adverse effects after consuming recalled products should seek medical attention immediately.
These cases of plastic contamination underscore the importance of seeking sustainable alternatives to plastic packaging. It's necessary to reduce the reliance on single-use plastics in food products due to the hazards they can pose.
Supporting initiatives such as the development of biodegradable solutions and reusable food wraps are among the small changes that can go a long way toward reducing microplastic pollution and protecting the planet.
Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia
-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions, today announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of EM–221, the company's investigational phosphodiesterase 10A (PDE10A) inhibitor, in patients with schizophrenia. "This IND clearance represents a major milestone for EuMentis as we advance EM–221 through Phase 2 clinical development," said Frank Stonebanks, Chief Executive Officer of EuMentis. "EM–221 is more than a single asset—it represents a pipeline in a product with potential applications across multiple neuropsychiatric and neurodevelopmental conditions. As we enter this next phase, we're excited by the opportunity to unlock significant therapeutic and commercial value in schizophrenia and beyond, supported by a world-class team and leading scientific collaborators." EM-221 is targeting PDE10A, a key intracellular enzyme that regulates dopamine and glutamate signaling in brain regions implicated in schizophrenia. Unlike traditional antipsychotics that broadly block dopamine receptors and are associated with serious side effects such as weight gain, movement disorders, and sedation, PDE10A inhibition offers a more targeted mechanism that modulates these pathways without direct receptor antagonism. "We are very excited to receive IND clearance from the FDA for schizophrenia, which is a serious, lifelong disorder affecting nearly 4 million adults and adolescents in the U.S. alone," said Dr. Randall Marshall, Chief Medical Officer of EuMentis. "There is a wealth of data suggesting that a PDE10A inhibitor can benefit individuals with schizophrenia as a more effective, safer, and better-tolerated therapy. We look forward to initiating our Phase 2 study of EM-221 later this year." EM–221 is a next-generation, selective PDE10A inhibitor designed to maximize efficacy while minimizing off-target effects. Preclinical and phase 1 clinical studies suggest EM–221 may offer superior tolerability and a broader therapeutic window, positioning it as a potential best-in-class treatment for both the positive and negative symptoms of schizophrenia—a critical gap left unaddressed by current therapies. "Despite decades of use, current dopamine receptor-blocking antipsychotic medications remain limited in their tolerability and effectiveness which make them unacceptable to many patients," said Dr. John Krystal, Robert L. McNeil, Jr. Professor of Translational Research and Chair of Psychiatry at Yale School of Medicine. "The PDE10A mechanism represents an important and innovative approach to modulating dopaminergic and glutamatergic signaling in the brain. I'm encouraged by the potential of EM–221 to offer a new therapeutic option for patients who urgently need safer and more effective treatments." About EM-221 EuMentis is building a pipeline-in-a-product around EM-221. EM-221 is an innovative product that targets the phosphodiesterase 10A enzyme, uniquely concentrated in the brain's striatum, to enhance cyclic nucleotide signaling and balance dopamine pathways. Unlike traditional antipsychotics, it offers the potential to address not only the positive symptoms like hallucinations but also the challenging negative symptoms—such as social withdrawal, blunted emotions and difficulty planning—that often persist untreated. EM-221 has been cleared by the U.S. FDA for Phase 2 evaluation, and the company expects to begin dosing in its first clinical trial in the second half of 2025. About EuMentis Therapeutics EuMentis is a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions. EuMentis is committed to leading innovation in the neuropsychiatric disease field by advancing programs that target selective CNS circuits in the brain with clinically validated mechanisms of action. This approach will enable its therapies to achieve better efficacy and tolerability, with the goal to deliver improved outcomes for patients. The Company's lead product, EM-221, is a potentially groundbreaking advancement in schizophrenia treatment, with a new, differentiated PDE10A inhibitor. Developed through years of rigorous research, this breakthrough heralds a new era of hope, aiming to improve overall quality of life for those affected by schizophrenia with a novel mechanism that's both precise and promising. EuMentis is headquartered in San Diego, CA. For more information, please visit and engage with us on LinkedIn. Media ContactAmy ConradJuniper Pointamy@ Company ContactFrank StonebanksCEOfstonebanks@ View original content to download multimedia: SOURCE EuMentis Therapeutics, Inc. Sign in to access your portfolio


Business Wire
28 minutes ago
- Business Wire
QualiZeal Welcomes Healthcare Industry Visionary Dr. Aiman Abdel-Malek to Business Advisory Board
DALLAS--(BUSINESS WIRE)--QualiZeal Inc., the world's fastest-growing Quality Engineering (QE) services company, announced the appointment of renowned healthcare industry visionary Dr. Aiman Abdel-Malek to its Business Advisory Board. This strategic move aims to leverage Dr. Abdel-Malek's transformative leadership experience in the healthcare, life sciences, and medical devices sectors as QualiZeal fortifies its position as a leader in the enterprise digital transformation landscape. With more than 25 years in executive leadership roles at GE, Qualcomm, and Insulet Corporation, Dr. Abdel-Malek is a recognized expert in secure, connected diabetes management systems and mobile healthcare solutions. Under his distinguished leadership, Insulet launched the world's first FDA-cleared, smartphone-controlled tubeless insulin patch pump and artificial pancreas. With over 40 patents and publications in secure connected healthcare, digital care delivery, and safe AI, he serves as a board advisor to several companies driving personalized healthcare innovation through digital technology and AI. "Welcoming Dr. Aiman Abdel-Malek to our Business Advisory Board is a tremendous honor," said Kalyan Konda, Co-Founder, Executive Director, and CEO of QualiZeal. "His proven track record in AI-driven healthcare breakthroughs will provide invaluable strategic guidance as we solidify our market leadership and advance toward our goal of quadrupling the company by 2028. Dr. Abdel-Malek's strategic counsel will be crucial in shaping our next generation of innovation, expanding our global impact, and solidifying our position as a leader in modern quality engineering." Dr. Aiman Abdel-Malek shared his enthusiasm about the partnership, stating, 'I believe QualiZeal will redefine how Quality Engineering is being practiced. The highly innovative, patent-pending QMentisAI platform is truly a game-changer. It's the industry's most complete end-to-end GenAI-powered QE platform, dramatically accelerating the journey from functional requirements to automated testing with regulatory-grade precision, reducing process times by over 60%. Backed by visionary leadership and a world-class team, QualiZeal has the clarity, innovation, and momentum to lead the industry. I'm proud to join them on this exciting journey.' About QualiZeal: QualiZeal is the world's fastest-growing Quality Engineering (QE) services company, known for its automation-first, AI-led, and platform-driven approach to software quality. With a diverse portfolio of digital transformation services—including Quality Engineering, Digital Engineering, Advisory & Transformation, and Emerging Technology Testing—QualiZeal empowers leading global organizations to achieve quality excellence and sustainable market leadership. QualiZeal's award-winning proprietary platforms, QMentisAI (patent-pending) and QualiCentral, pioneer the innovative use of AI and GenAI to solve complex QE challenges at speed and scale for clients in their digital transformation journeys. Recognized by Gartner, Everest Group, Forrester, Frost & Sullivan, and NelsonHall, the company has received numerous accolades, including the 2025 Gold Stevie® Award for Fastest Growing Tech Company of the Year (American Business Awards®). Trusted by 70+ global enterprise clients and backed by 850+ elite quality engineers, QualiZeal drives seamless digital transformation—reflected in its industry-leading Net Promoter Score (NPS) of 75. For more information, please visit


Boston Globe
an hour ago
- Boston Globe
FDA vaccine chief leaving agency after less than 3 months
Prasad joined the FDA in May after years as an academic researcher at the University of California San Francisco, where he frequently criticized the FDA's approach to drug approvals and COVID-19 vaccines. Advertisement His contrarian approach appeared to match FDA Commissioner Marty Makary, who repeatedly praised Prasad's work and intellect. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up But in recent weeks Prasad became a target of conservative activists, including Laura Loomer, who flagged Prasad's past statements criticizing Trump and praising liberal independent Senator Bernie Sanders. 'How did this Trump-hating Bernie Bro get into the Trump admin???' Loomer posted on X last week. Prasad also attracted scrutiny for his handling of a recent safety issue surrounding the only approved gene therapy for Duchenne's muscular dystrophy. Under his direction, shipments of the therapy were briefly halted after a series of patient deaths, then resumed late Monday following vocal pushback from families of boys with the fatal muscle-wasting disorder. Prasad has long been skeptical of the therapy and other muscular dystrophy drugs sold by the drugmaker, Sarepta Therapeutics. As an academic, Prasad gained prominence by attacking the FDA for being too lenient in its standards for approving cancer drugs and other new therapies. Advertisement That approach is at odds with Trump's Republican supporters, who generally favor speedier approvals and unfettered access to experimental treatments. During Trump's first term he signed the " Right to Try " law, a largely symbolic piece of legislation that won popular support from conservatives seeking to give dying patients expanded access to unproven drugs. Prasad's decision to pause Sarepta's therapy was criticized last week by a columnist and the editorial board of The Wall Street Journal. Separately, Prasad's division issued rejection letters this month to three small biotech firms seeking approval for new gene therapies. Prasad's predecessor in the role, Dr. Peter Marks, oversaw a steep rise in approvals for new gene therapies, which aim to treat or prevent disease by replacing or modifying a portion of patients' genetic code. Prasad has been an outspoken critic of Marks' leadership at FDA. which included overseeing the approval of the first COVID vaccines and therapies.